FY2025 Earnings Forecast for CGTX Issued By HC Wainwright

Key Points

• HC Wainwright has upgraded its earnings per share estimate for Cognition Therapeutics for FY2025 from ($0.36) to ($0.33) and maintains a "Buy" rating with a price target of $3.00.
• Cognition Therapeutics reported ($0.11) EPS for the last quarter, exceeding the consensus estimate of ($0.12).
• Institutional investors currently hold 43.35% of Cognition Therapeutics' stock, showing increased confidence among hedge funds in recent trading activities.

Cognition Therapeutics, Inc. (NASDAQ:CGTX - Free Report) - Equities research analysts at HC Wainwright upped their FY2025 EPS estimates for Cognition Therapeutics in a research note issued on Monday, August 11th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($0.33) per share for the year, up from their prior forecast of ($0.36). HC Wainwright has a "Buy" rating and a $3.00 price objective on the stock. The consensus estimate for Cognition Therapeutics' current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for Cognition Therapeutics' Q1 2026 earnings at ($0.04) EPS, Q2 2026 earnings at ($0.04) EPS, Q3 2026 earnings at ($0.04) EPS, Q4 2026 earnings at ($0.04) EPS and FY2026 earnings at ($0.15) EPS.

CGTX has been the subject of a number of other research reports. Wall Street Zen downgraded shares of Cognition Therapeutics to a "strong sell" rating in a research note on Saturday, July 12th. Chardan Capital reissued a "buy" rating and issued a $4.00 target price on shares of Cognition Therapeutics in a report on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating and three have given a Buy rating to the company. According to data from MarketBeat.com, Cognition Therapeutics presently has an average rating of "Buy" and a consensus price target of $2.83.

Cognition Therapeutics Trading Up 1.0%

CGTX traded up $0.0150 on Thursday, hitting $1.5050. 1,761,917 shares of the company were exchanged, compared to its average volume of 4,528,444. The firm has a 50-day moving average price of $0.62 and a two-hundred day moving average price of $0.49. Cognition Therapeutics has a twelve month low of $0.2223 and a twelve month high of $1.97. The company has a market cap of $110.57 million, a price-to-earnings ratio of -2.23 and a beta of 1.00.

Cognition Therapeutics (NASDAQ:CGTX - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.12) by $0.01.

Institutional Investors Weigh In On Cognition Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of CGTX. Two Sigma Investments LP boosted its holdings in shares of Cognition Therapeutics by 372.2% during the fourth quarter. Two Sigma Investments LP now owns 53,691 shares of the company's stock worth $38,000 after purchasing an additional 42,321 shares during the last quarter. Northeast Financial Consultants Inc boosted its position in shares of Cognition Therapeutics by 158.6% in the first quarter. Northeast Financial Consultants Inc now owns 63,351 shares of the company's stock worth $27,000 after buying an additional 38,851 shares during the period. Geode Capital Management LLC lifted its position in Cognition Therapeutics by 8.9% during the 4th quarter. Geode Capital Management LLC now owns 352,348 shares of the company's stock worth $247,000 after acquiring an additional 28,705 shares in the last quarter. CM Management LLC lifted its position in Cognition Therapeutics by 100.0% during the 1st quarter. CM Management LLC now owns 400,000 shares of the company's stock worth $168,000 after acquiring an additional 200,000 shares in the last quarter. Finally, Voss Capital LP purchased a new position in Cognition Therapeutics in the 4th quarter worth approximately $351,000. Hedge funds and other institutional investors own 43.35% of the company's stock.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.